Among patients with rheumatoid arthritis, those who are obese are more likely to have worse disease activity, lower functional ability and poorer health-related quality of life compared with their nonobese counterparts, a study has found.
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
The high-concentration capsaicin patch shows promise in the management of painful diabetic peripheral neuropathy (PDPN), with an effect that is similar to that observed with oral agents but offering systemic tolerability benefits, according to a network meta-analysis.